Phenylbutyrate is recommended in urea cycle disorders and liver injury to enhance nitrogen disposal by the urine. However, hypothetically there may be adverse responses to the use of phenylbutyrate in the treatment of liver disease because of its role as a histone deacetylase inhibitor and its stimulatory effect on branched-chain alpha-keto acid dehydrogenase, the rate-limiting enzyme in the catabolism of branched-chain amino acids (BCAA; valine, leucine and isoleucine). We report the effects of phenylbutyrate on liver regeneration and amino acid levels in plasma of partially hepatectomized (PH) rats. Phenylbutyrate or saline was administered at 12-h intervals to PH or laparotomized rats. Phenylbutyrate delayed the onset of liver regeneration compared to the saline-treated controls, as indicated by lower hepatic DNA specific activities 18 and 24( ) h post-PH, decreased hepatic fractional protein synthesis rates 24 h post-PH and lowered the increases in liver weights and hepatic protein and DNA contents 48 h after PH. Hepatic DNA fragmentation (a hallmark of apoptosis) was higher in the phenylbutyrate-treated animals than in controls. Phenylbutyrate decreased the glutamine and BCAA concentrations and the ratio of the BCAA to aromatic amino acids (phenylalanine and tyrosine) in the blood plasma in both hepatectomized and laparotomized animals. In conclusion, the delayed onset of liver regeneration and the decrease in BCAA/AAA ratio in blood suggest that phenylbutyrate administration may be disastrous in subjects with acute hepatic injury and BCAA supplementation is needed when phenylbutyrate is used therapeutically.

Department of Physiology Faculty of Medicine in Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

Zobrazit více v PubMed

Ben Mosbah I., Alfany‐Fernández I., Martel C. et al (2010) Endoplasmic reticulum stress inhibition protects steatotic and non‐steatotic livers in partial hepatectomy under ischemia‐reperfusion. Cell Death Dis. 1, e52. PubMed PMC

Bolden J.E., Peart M.J. & Johnstone R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769–784. PubMed

Brunetti‐Pierri N., Lanpher B., Erez A. et al (2011) Phenylbutyrate therapy for maple syrup urine disease. Hum. Mol. Genet. 20, 631–640. PubMed PMC

Brusilow S.W. (1991) Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion. Pediatr. Res. 29, 147–150. PubMed

Bucher N.L.R. (1967) Experimental aspects of hepatic regeneration. N. Engl. J. Med. 277, 686–696. PubMed

Bucher N.L.R. & Swaffield M.N. (1964) The rate of incorporation of labeled thymidine into the deoxyribonucleic acid of regenerating rat liver in relation to the amount of liver excised. Cancer Res. 24, 1611–1625. PubMed

Burrage L.C., Jain M., Gandolfo L., Lee B.H., Members of the Urea Cycle Disorders Consortium , Nagamani S.C. (2014) Sodium phenylbutyrate decreases plasma branched‐chain amino acids in patients with urea cycle disorders. Mol. Genet. Metab. 113, 131–135. PubMed PMC

Burton K. (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem. J. 62, 315–323. PubMed PMC

Carducci M.A., Nelson J.B., Chan‐Tack K.M. et al (1996) Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. 2, 379–387. PubMed

Davies N.A., Wright G., Ytrebø L.M. et al (2009) L‐ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 50, 155–164. PubMed

Enns G.M., Berry S.A., Berry G.T., Rhead W.J., Brusilow S.W. & Hamosh A. (2007) Survival after treatment with phenylacetate and benzoate for urea‐cycle disorders. N. Engl. J. Med. 356, 2282–2292. PubMed

Fischer J.E. & Baldessarini R.J. (1971) False neurotransmitters and hepatic failure. Lancet 2(7715), 75–80. PubMed

Garlick P.J., McNurlan M.A. & Preedy V.R. (1980) A rapid and convenient technique for measuring the rate of protein synthesis in tissue by injection of [3H]phenylalanine. Biochem. J. 192, 719–723. PubMed PMC

Gomes‐Marcondes M.C.C. & Tisdale M.J. (2002) Induction of protein catabolism and the ubiquitin‐proteasome pathway by mild oxidative stress. Cancer Lett. 180, 69–74. PubMed

Higgins G.M. & Anderson R.M. (1931) Experimental pathology of the liver. I. Restoration of liver of white rat following partial surgical removal. Arch. Pathol. 12, 186–202.

Holecek M. (2014) Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy‐therapeutic perspectives. Metab. Brain Dis. 29, 9–17. PubMed PMC

Holecek M. & Kovarik M. (2011) Alterations in protein metabolism and amino acid concentrations in rats fed by a high‐protein (casein‐enriched) diet ‐ effect of starvation. Food Chem. Toxicol. 49, 3336–3342. PubMed

Holecek M., Simek J., Kruf M. & Zadak Z. (1985) Effect of branched chain amino acids on liver regeneration after partial hepatectomy. Physiol. Bohemoslov. 34, 359–366. PubMed

Holecek M., Simek J., Dvorackova I., Subrtova D. & Palicka V. (1986) Spontaneous ingestion of different types of carbohydrates in rats with liver damage and their effect on liver repair. Cs. Gastroenterol. Vyziva 40, 268–275.

Holecek M., Simek J., Palicka V. & Zadak Z. (1991) Effect of glucose and branched chain amino acid (BCAA) infusion on onset of liver regeneration and plasma amino acid pattern in partially hepatectomized rats. J. Hepatol. 13, 14–20. PubMed

Huang J., Barr E. & Rudnick D.A. (2013) Characterization of the regulation and function of zinc‐dependent histone deacetylases during rodent liver regeneration. Hepatology 57, 1742–1751. PubMed PMC

Ke Q., Yang R.N., Ye F. et al (2012) Impairment of liver regeneration by the histone deacetylase inhibitor valproic acid in mice. J. Zhejiang Univ. Sci. B 13, 695–706. PubMed PMC

Koohmaraie M. & Kretchmar D.H. (1990) Comparisons of four methods for quantification of lysosomal cysteine proteinase activities. J. Anim. Sci. 68, 2362–2370. PubMed

Lowry O.H., Rosebrough N.J., Farr A.L. & Randall R.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265–275. PubMed

McGuire B.M., Zupanets I.A., Lowe M.E. et al (2010) Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 51, 2077–2085. PubMed PMC

McNurlan M.A., Tomkins A.M. & Garlick P.J. (1979) The effect of starvation on the rate of protein synthesis in rat liver and small intestine. Biochem. J. 178, 373–379. PubMed PMC

Nair K.S. & Short K.R. (2005) Hormonal and signaling role of branched‐chain amino acids. J. Nutr. 135, 1547S–1552S. PubMed

Rockey D.C., Vierling J.M., Mantry P. et al (2014) Randomized, double‐blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 59, 1073–1083. PubMed PMC

Scaglia F., Carter S., O'Brien W.E. & Lee B. (2004) Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol. Genet. Metab. 81, S79–S85. PubMed

Welle S. (1999) Methods for studying protein metabolism in humans Welle S, pp. 29–71. New‐York: Human protein metabolism. Springer‐Verlag.

Wilcken B. (2004) Problems in the management of urea cycle disorders. Mol. Genet. Metab. 81, S86–S91. PubMed

Yoshida S., Yunoki T., Aoyagi K. et al (1995) Effect of glutamine supplement and hepatectomy on DNA and protein synthesis in the remnant liver. J. Surg. Res. 59, 475–481. PubMed

Zhang X., Wei L., Yang Y. & Yu Q. (2004) Sodium 4‐phenylbutyrate induces apoptosis of human lung carcinoma cells through activating JNK pathway. J. Cell. Biochem. 93, 819–829. PubMed

Muscle Amino Acid and Adenine Nucleotide Metabolism during Exercise and in Liver Cirrhosis: Speculations on How to Reduce the Harmful Effects of Ammonia

Branched-Chain Amino Acids and Branched-Chain Keto Acids in Hyperammonemic States: Metabolism and as Supplements

Acute effects of phenylbutyrate on glutamine, branched-chain amino acid and protein metabolism in skeletal muscles of rats